OBJECTIVE AND DESIGN: This study exploits the biological activity of interleukin (IL)-3 to generate high yields of peritoneal mast cells ex vivo in order to examine pro-inflammatory immune responses in ex-vivo culture. MATERIAL OR SUBJECTS: Mast cells were obtained from the peritoneal cavity of C57BL/6 mice. TREATMENT: Mice were injected intraperitoneally twice per day for 5 days with IL-3 (40-50 μg/ml) to increase mast cell numbers. METHODS: Histological studies examined mast cell numbers in the peritoneal cavity, intestine, lung, spleen and skeletal muscle. Peritoneal mast cells cultured ex vivo (PCMCs) were stimulated for 24 h with lipopolysaccharide and Bordetella pertussis antigen and secretion of tumour necrosis factor-α, IL-6, IL-4, IL-5, IL-10 and interferon-γ into supernatant was measured by commercial ELISA. Cell surface marker expression of FcεRI, c-kit, OX40L and TLR2 was measured by flow cytometry. Mast cell degranulation was measured using a β-hexosaminidase assay. RESULTS: IL-3 treatment increases mast cell numbers in the peritoneal cavity, spleen and muscle but not intestine and lung of C57BL/6 mice. PCMCs generated from IL-3-treated mice exhibit impaired growth, differentiation and responses to activation as measured by decreased cytokine secretion and cell surface marker expression. CONCLUSION: Mast cells cultured from IL-3-treated mice show impaired responses.
OBJECTIVE AND DESIGN: This study exploits the biological activity of interleukin (IL)-3 to generate high yields of peritoneal mast cells ex vivo in order to examine pro-inflammatory immune responses in ex-vivo culture. MATERIAL OR SUBJECTS: Mast cells were obtained from the peritoneal cavity of C57BL/6 mice. TREATMENT: Mice were injected intraperitoneally twice per day for 5 days with IL-3 (40-50 μg/ml) to increase mast cell numbers. METHODS: Histological studies examined mast cell numbers in the peritoneal cavity, intestine, lung, spleen and skeletal muscle. Peritoneal mast cells cultured ex vivo (PCMCs) were stimulated for 24 h with lipopolysaccharide and Bordetella pertussis antigen and secretion of tumour necrosis factor-α, IL-6, IL-4, IL-5, IL-10 and interferon-γ into supernatant was measured by commercial ELISA. Cell surface marker expression of FcεRI, c-kit, OX40L and TLR2 was measured by flow cytometry. Mast cell degranulation was measured using a β-hexosaminidase assay. RESULTS:IL-3 treatment increases mast cell numbers in the peritoneal cavity, spleen and muscle but not intestine and lung of C57BL/6 mice. PCMCs generated from IL-3-treated mice exhibit impaired growth, differentiation and responses to activation as measured by decreased cytokine secretion and cell surface marker expression. CONCLUSION: Mast cells cultured from IL-3-treated mice show impaired responses.
Authors: Thomas Hochdörfer; Marcel Kuhny; Carolin N Zorn; Rudi W Hendriks; Bart Vanhaesebroeck; Thomas Bohnacker; Gerald Krystal; Michael Huber Journal: Cell Signal Date: 2011-01-22 Impact factor: 4.315
Authors: A Solís-López; U Kriebs; A Marx; S Mannebach; W B Liedtke; M J Caterina; M Freichel; V V Tsvilovskyy Journal: PLoS One Date: 2017-02-03 Impact factor: 3.240
Authors: Ibrahim Alkanfari; Katie B Freeman; Saptarshi Roy; Tahsin Jahan; Richard W Scott; Hydar Ali Journal: Cells Date: 2019-04-03 Impact factor: 6.600
Authors: Krisztina V Vukman; Andrea Ferencz; Daniella Fehér; Krisztina Juhos; Péter Lőrincz; Tamás Visnovitz; Anna Koncz; Krisztina Pálóczi; Gábor Seregélyes; András Försönits; Delaram Khamari; Alicia Galinsoga; László Drahos; Edit I Buzás Journal: J Extracell Vesicles Date: 2021-01-09
Authors: Elizabeth Anderson; Kathrin Stavenhagen; Daniel Kolarich; Christian P Sommerhoff; Marcus Maurer; Martin Metz Journal: Front Immunol Date: 2018-07-09 Impact factor: 7.561